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Objective: Management of late fetal growth restriction (FGR) is limited to adequate
fetal monitoring and optimal timing of delivery. The Disproportionate Intrauterine Growth
Intervention Trial At Term (DIGITAT) trial compared induction of labor with expectant
management in pregnancies at (near) term complicated by suspected FGR. Findings
of the DIGITAT trial were that expectant monitoring prolonged pregnancy for 10 days
and increased birth weight with only 130 grams. This resulted in more infants born below
the 2.3rd percentile compared to induction of labor, respectively, 12.5% in induction of
labor and 30.6% in expectant monitoring group. The main placental lesions associated
with FGR are maternal vascular malperfusion, fetal vascular malperfusion, and villitis of
unknown etiology. We investigated whether placentas of pregnancies complicated with
FGR in the expectant monitoring group reveal more and more severe pathology due to
pregnancy prolongation.
Material and methods: The DIGITAT trial was a multicenter, randomized controlled
trial with suspected FGR beyond 36 + 0 weeks. We now analyzed all available
cases (n = 191) for placental pathology. The macroscopic details were collected and
histological slides were recorded and classified by a single perinatal pathologist, blinded
for pregnancy details and outcome. The different placental lesions were scored based on
the latest international criteria for placental lesions as defined in the Amsterdam Placental
Workshop Group Consensus Statement.
Results: The presence of maternal vascular malperfusion and chorioamnionitis were
higher in the expectant management group (p < 0.05 and p < 0.01, respectively). No
differences in placental weight and maturation of the placenta between the induction
of labor and the expectant management group were seen. Fetal vascular malperfusion,
villitis of unknown etiology and nucleated red blood cell count did not differ between
the groups.
Feenstra et al. Placental Pathology in FGR at Term
Conclusion: Expectant management of late FGR is associated with increased maternal
vascular malperfusion and chorioamnionitis. This may have implications for fetal and
neonatal outcome, such as programming in the developing child influencing health
outcomes later in life.
Keywords: fetal growth restriction, placental pathology, DIGITAT trial, maternal vascular malperfusion,
chorioamnionitis
INTRODUCTION
Fetal growth restriction (FGR) is a condition in pregnancy
in which the fetus fails to reach its growth potential. FGR
affects up to 15% of all pregnancies (1, 2) and is not only
associated with mortality, but also with long term morbidity (3–
5). Appropriate placental nutrient and oxygen supply is essential
for normal fetal growth. The origin of placental insufficiency
is multifactorial (6, 7). Several types of lesions can be found
in placentas of pregnancies complicated by FGR (7–9). The
main placental lesions found in FGR placentas are maternal
vascular malperfusion, fetal vascular malperfusion, and villitis
of unknown etiology (9). Elevated nucleated red blood cells are
considered as an indication of fetal hypoxia (10, 11). Other
rare findings in placentas of FGR complicated pregnancies
include chronic histiocytic intervillositis and massive perivillous
fibrinoid deposition (12, 13).
Until now, adequate fetal monitoring and optimal timing of
delivery are the only possible interventions for FGR as other
therapeutic options are lacking (14). Timing of delivery in case of
FGR is balanced between (relative) prematurity on the one side
and prolonged undernutrition/hypoxia on the other side. The
DIGITAT study investigated whether timely delivery in (near)
term FGR would result in better outcomes. The primary analysis
(36 + 0 till 41 + 0 weeks of gestation) showed equivalence in
composite neonatal outcome between expectant monitoring and
induction of labor (15, 16). Sub analysis revealed that the optimal
time to minimize neonatal consequences is delivery around 38
weeks of gestation, when benefits of a planned delivery outweigh
consequences of prolongation of pregnancy, as this is associated
with a longer exposure to a malnourished environment (17).
The DIGITAT trial found that expectant monitoring resulted
in a pregnancy prolongation of a further 10 days compared to
those in the immediate induction group. This was associated
with an increase of only 130 grams in the birth weight of
those expectantly managed and a higher proportion of infants
born below the 2.3 percentile (30.6% compared to 12.5% in the
immediate induction of labor group).
In this study we investigate whether placentas of pregnancies
complicated with FGR at (near) term show specific features
due to prolongation of pregnancy. The aim of this study is to
assess the structural impact on the placenta when pregnancy is
prolonged in FGR at term.
MATERIALS AND METHODS
DIGITAT-Original Study Design
The Disproportionate Intrauterine Growth Intervention Trial At
Term (DIGITAT) trial was a multicenter, randomized controlled
trial of women pregnant with a singleton fetus with suspected
FGR from 36 + 0 till 41 + 0 weeks of gestation onwards.
Details of the DIGITAT trial protocol have been described
elsewhere (15). In brief, consenting and eligible women were
randomized to either expectant monitoring or induction of
labor. The expectant monitoring group was monitored until the
onset of spontaneous delivery or when for other reasons than
suspected FGR an indication for delivery became apparent. In the
induction of labor group delivery was induced within 48 h after
randomization (17, 18).
Data Collection of Further Analysis
(Current Study)
All participating hospitals in the DIGITAT trial were asked to
evaluate whether the placentas of their trial participants had been
examined by a local pathologist. If so, all available material such
as pathology reports, histologic slides, and tissue blocks were
collected and re-analyzed. The analyses included details of the
macroscopic description of the placental disk, membranes and
umbilical cord as described in the placental pathology report.
Furthermore, the histologic slides, routinely stained with
Hematoxylin and Eosin (H&E) were revised, scored and classified
to latest international criteria (9) by a single perinatal pathologist
(MS), who was blinded for pregnancy details and outcome.
Placental Histology
The various placental lesions were evaluated based on the latest
international criteria for placental lesions as described in the
Amsterdam Placental Workshop Group Consensus Statement
(9). Lesions evaluated were placental pathology consistent
with maternal vascular malperfusion (MVM), fetal vascular
malperfusion (FVM), chorioamnionitis (CA), villitis of unknown
etiology (VUE), elevated nucleated red blood cell count (NRBC),
chronic histiocytic intervillositis (CHI), and massive perivillous
fibrin deposition (MPVFD). Also, if available, placental weight,
placental weight percentile, birth weight placenta weight ratio
(BWPW) (19), umbilical cord length and coiling index were
included in the analyzes. The coiling index was calculated by
dividing the number of whole coils by the umbilical cord length
in centimeters. A normal coiling index is considered to be
between 0.1 and 0.3. Due to the retrospective nature of this
analysis unfortunately no other placental characteristic data (like
the extension of infarction) were available.
Statistical Analysis
SPSS 24.0 software forWindows (SPSS Inc. Chicago, IL) was used
for the statistical analyses. Continued variables were evaluated
with a two-tailed unpaired T-test and binary or categorical
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variables were evaluated with a Fisher Exact Test. Statistical
significance was assumed at p < 0.05.
RESULTS
A total of 191 cases were available for review of placental
pathology, respectively, 97 (321 in the original DIGITAT
trail) participants in the induction of labor group and 94
(329 in original DIGITAT trail) participants in the expectant
monitoring group.
In contrast to the original DIGITAT study the baseline
characteristics of the two groups were statistically different
for parity, maternal smoking and BMI (Table 1). Similar
to the original DIGITAT study gestational hypertension was
significantly higher in the expectant monitoring group. In
the DIGITAT trial pre-eclampsia was more prominent in the
expectant monitoring group than in the induction of labor group,
but in our cohort of this re-analysis no significant difference was
seen in the presence of pre-eclampsia.
Most women in the current analysis met the DIGITAT study
criteria of FGR by combinations of inclusion criteria, usually by
a fetal abdominal circumference (AC) below the 10th percentile
(respectively n= 74 in induction of labor and n= 77 in expectant
monitoring) and/or an estimated fetal weight (EFW) below the
10th percentile (respectively n= 92 in the induction of labor and
n = 72 in the expectant monitoring). Furthermore, a decline in
AC growthwas also a criterium for study inclusion (not as a single
criterium, but in combination with either AC or EFW below p10)
and was differently observed between the groups, with a higher
presence in the expectant monitoring group (induction of labor
was n= 14 and expectant monitoring n= 24; p< 0.05) (Table 1).
In the expectant monitoring group in 51 of the 94 cases labor
was induced due to eithermaternal indication (8), fetal indication
(20), combined maternal and fetal indication (4), or rupture of
membranes (2) (Table 1).
In the current analysis, women in the expectant monitoring
group had a longer gestational age (8 days), compared to
the induction of labor group (p < 0.01). This is slightly less
prolongation than in the original DIGITAT study in which
pregnancy was prolonged by 10 days. Birth weight in the study
population of this sub analysis was not significantly different
between the groups. However, there was a difference of 60
grams between the expectant management and induction of
labor, which means a weight gain of 60 grams in the achieved
8 days of pregnancy prolongation. This is also slightly less than
in the original DIGITAT study (with 130 grams weight gain
in 10 days) (Table 1). The average neonatal stay in hospital
was approximately 8 days in both groups. A few cases needed
admission to the neonatal intensive care unit, significantly more
in the expectant monitoring group (p < 0.05). The length of
stay in the neonatal intensive care unit was approximately 6
days for both groups. There were no neonatal deaths reported
in both groups.
Placental Characteristics
In Table 2 placental characteristics are described of both the
induction of labor group and the expectant monitoring group.
No differences in placental weight, umbilical cord length, coiling
index and BWPW ratio were found between the two groups.
Placental Histology
The findings of placental histology in both groups are described
in Table 3. Maturation of the placenta was similar in both groups.
Maternal vascular malperfusion (MVM) was significantly higher
in the expectant monitoring group compared to the induction
of labor group (p < 0.05). Fetal vascular malperfusion (FVM)
was similar in both groups. In placentas from the expectant
monitoring group we found a significantly higher incidence of
chorioamnionitis (CA) (p < 0.01). The presence of villitis of
unknown etiology (VUE) and the nucleated red blood cell count
(NRBC) was similar in both groups. Rare placental findings like
chronic histiocytic intervillositis (CHI) and massive perivillous
fibrinoid deposition (MPFD) were seen in a few cases (n = 2 for
CHI in the induction group and 0 in the expectant monitoring
group; n = 4 and n = 1 for MPFD in the induction group and
expectant monitoring group, respectively).
DISCUSSION
In this sub analysis of the DIGITAT study we found that
maternal vascular malperfusion (MVM) occurred significantly
more often in the expectant monitoring group in comparison
to the induction of labor group (p < 0.05) in (near) term FGR.
Moreover, participants in the expectant monitoring group had
a significantly higher incidence of chorioamnionitis (CA) (p <
0.01). The DIGITAT trial previously showed no differences in
composite neonatal outcome between expectant monitoring and
induction of labor, however, it was seen that the average weight
gain was only 130 grams in 10 days delivery delay, which resulted
in more babies born with a birth weight below the p2.3. The
follow up study of the original DIGITAT trial at 2 years of
age showed that babies born with a birth weight below p2.3
scored lower at the ages and stages questionnaire (ASQ) for
developmental disorders.
MVM occurs early in pregnancy and is likely due to
maladaptation of the spiral arteries. It develops over time when
gestation prolongs (21, 22). By inadequate remodeling of spiral
arteries a high resistance flow induces shear stress and damage to
parenchyma, like infarctions, and differences in oxygen tension
leading to oxidative stress and free radical damage (12, 22–25).
The higher prevalence of MVM in the expectant monitoring
group could be caused by a prolonged time of hypoxia caused
by inadequate maternal vascularization. This could further
lead to increase in cellular stress, e.g., oxidative stress and
endoplasmic reticulum (ER) stress. This may ultimately lead
to an increase in the occurrence of FGR and development of
preeclampsia (23–26).
To support this theory of prolonged exposure to a pathologic
environment, a significant higher prevalence of the development
of gestational hypertension in the expectant monitoring group
was seen. MVM has been described to be causal in gestational
hypertension and preeclampsia (20, 27). This finding further
strengthens the clinical experience that expectant monitoring or
prolongation of pregnancy in FGR at (near) term is not without
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TABLE 1 | Demographic and baseline characteristics of the selected randomized participants for this analysis of placental pathology in FGR at term.
Baseline characteristics Induction of labor (n = 97) Expectant monitoring (n = 94) Sig.
Nulliparous (%) 48 37 p = 0.013
Maternal age (years) 28.07 ± 5.58 27.65 ± 5.41 p = 0.500
BMI at study entry (kg/m2) 24.31 ± 6.09 23.18 ± 4.82 p = 0.024
Maternal smoking 58 39 p = 0.010
Gestational hypertension 7 13 p = 0.035
Pre-eclampsia 6 9 p = 0.150
INCLUSION CRITERIA
Fetal abdominal circumference <10th percentile 76 82 p = 0.211
Estimated fetal weight <10th percentile 95 76 p = 0.224
Deceleration of fetal abdominal circumference curve 14 26 p = 0.038
MODE OF DELIVERY
Induced labor 95 51 p = 0.001
Vaginal delivery 43 39 p = 0.100
Vaginal instrumental 33 34 p = 0.352
Cesarean section 24 27 p = 0.248
NEONATAL CHARACTERISTICS
Gestational age at birth (days) 264 ± 7.71 272 ± 9.27 p = 0.010
Birth weight (grams) 2242.23 ± 285 2303.10 ± 365 p = 0.065
Length of neonatal stay in hospital (days) 8.9 ± 7.00 9.1 ± 8.41 p = 0.690
Admission to the neonatal intensive care unit (NICU) 2 5 p = 0.020
Data is presented as proportion, unless stated otherwise in the table. Significance is presented as p-value, a p < 0.05 is assumed significant.
TABLE 2 | Comparison of placental characteristics between the induction of labor
and expectant monitoring group in FGR at term.
Placental characteristics Induction of





Placental weight (grams) 371.49 ± 15.50 361.40 ± 15.54 p = 0.707
Umbilical cord length (cm) 35.44 ± 1.92 35.36 ± 1.93 p = 0.789
Coiling index 0.35 ± 0.189 0.30 ± 0.216 p = 0.483
Birth Weight to Placental
Weight ratio (BWPW)
6.29 ± 1.336 6.71 ± 1.787 p = 0.284
Data is presented as mean. Significance is presented as p-value, a p < 0.05 is assumed
significant. No statistical differences were found in placental characteristics.
risks especially for the mother (28), even though on short term
no differences were seen in neonatal outcome. A study from
Parra-Saavedra et al. implies in a group of late onset Small-for-
Gestational Age (SGA) that placental under perfusion (PUP)
can also lead to higher neonatal morbidity; in this study in
77/84 placentas maternal vascular supply was—as in our study-
compromised (29). Furthermore, similar to the original study,
in this sub-study a large group of women had labor induced
although being allocated to the expectant monitoring group
(51/94: 66%), indicating that the difference between the groups in
MVM is in fact an underestimation of what would really happen
when delivery was awaited.
The histologic diagnosis of chorioamnionitis (CA) is made
when an inflammatory infiltrate is seen in the chorioamniotic
membranes. At term CA is most frequently induced by
TABLE 3 | The comparison of placental pathology between induction of labor and








Maturation matching gestational age
(MAT)
89 82 p = 0.701
Maternal vascular malperfusion (MVM) 9 17 p = 0.049
Fetal vascular malperfusion (FVM) 10 16 p = 0.069
Chorioamnionitis (CA) 13 32 p = 0.010
Villitis of unknown etiology (VUE) 29 30 p = 0.507
Elevated nucleated Red Blood Cell
Count (NRBC)
2 3 p = 0.485
Chronic histiocytic intervillositis (CHI) 2 0 p = 0.257
Massive perivillous fibrinoid
deposition (MPFD)
4 1 p = 0.194
Data is presented as proportion in the table. Significance is presented as p-value, a
p < 0.05 is considered significant.
inflammation and cellular stress, in the absence of a
microorganism (30). During labor the uteroplacental blood
flow is compromised leading to hypoxia of the placenta and
its membranes. This leads to an increase in pro-inflammatory
markers in the placenta. In fact, labor at term has been associated
with infiltration of inflammatory cells in the placenta and higher
plasma levels of pro-inflammatory chemokines and cytokines,
such as Interleukin 6 (IL-6), Interleukin 8 (IL-8), and Tumor
Necrosis Factor alpha (TNF-alpha) (30–32). Hypothetically, the
inflammatory response in the chorioamniotic membranes and
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cervix could be the result of an increase in pro-inflammatory
cytokines caused by cellular stress, e.g., oxidative stress and ER
stress (23, 24, 33, 34).
Furthermore, even though in the expectant monitoring
group labor was often induced, significantly more spontaneous
deliveries took place in the expectant monitoring group.
Recent studies showed a higher incidence of histological
chorioamnionitis in spontaneous labor compared to,
respectively, induced labor, or cesarean section (33, 35).
This could be an additional explanation for the significantly
higher incidence of chorioamnionitis in the expectant
monitoring group.
In our analysis, we observed a higher prevalence of CA in
the expectant monitoring group. As described above, this is
conceivably explained by increase of pro-inflammatory cytokines
due to the prolonged hypoxic environment.
The incidence of fetal vascular malperfusion (FVM) was not
significantly different although a higher number of cases were
seen in the expectant monitoring group in comparison with
induction of labor.
Like MVM, FVM has been associated with fetal growth
restriction (FGR) due to decreased availability of functional
parenchyma (36). The etiology of FVM is however multifactorial
and not specifically related to FGR. FVM has been associated
with multiple factors as placental (for example umbilical cord
pathology), maternal (for example preeclampsia), and fetal (for
example cardiacmalformations) etiologies (6, 37, 38). Also, intra-
amniotic infection with a fetal response (vasculitis) and chronic
villitis of unknown etiology (VUE) are known associations (39).
In our study, villitis of unknown etiology (VUE) occurred
in approximately 30% of all cases, distributed equally between
both randomized groups. In existing literature, a broad range
of incidences of VUE is described, partly because the definition
has not been uniform and also due to differences in sampling
of placental parenchyma (40–43). With an equal distribution
between our groups, we conclude that prolonged pregnancy
in the expectant monitoring group is not associated with an
increased prevalence of VUE.
At term, normally only a small number of circulating
nucleated red blood cells (NRBCs) are seen in the fetal
circulation, if any (11). In response to fetal hypoxia the NRBC
count increases (10, 11). In our study, only a few cases showed
elevated NRBCs, suggesting that fetal monitoring to prevent fetal
hypoxia has been adequate in the two randomized groups as no
differences were seen in number of cases with elevated NRBCs.
In addition to the placental lesions described above, we also
investigated the presence of chronic histiocytic intervillositis
(CHI), massive perivillous fibrinoid deposition (MPFD), and
maternal floor infarction (MFI). These are rare placental lesions,
associated with (severe) FGR, with high recurrence risks (12, 13,
44–47). In our analyses, we found 2 cases of CHI in the induction
of labor group and none in the expectant monitoring group. Five
cases of MPFD were encountered, four of which in the induction
of labor group and one in the expectant monitoring group. No
cases with maternal floor infarction (MFI) were found in the total
study population. No significant differences were seen between
the induction of labor group and the expectant monitoring group
for CHI and MPFD.
We did not find any differences in placental weight or birth
weight to placental weight ratio (BWPW ratio) (Table 2). It
has been described that placental weight from fetuses with
FGR is significantly lower than placentas from fetuses with
a normal birth weight and that the BWPW ratio is higher,
although in fact fetal weight per placental unit is high and the
placenta performed well in that sense. A low BWPW ration
(a relatively low fetal weight per placental unit) has also been
described in relation to adverse outcome (19). Given the fact
that pregnancy prolongation resulted in only little weight gain
and placental weights were not different the BWPW ratio was,
as expected lower (although not significant) in the induction
group (8, 48, 49).
CONCLUSION
Placental pathology in FGR encompasses a broad group of
diagnoses, not exclusive for FGR. Our study shows that
expectant monitoring is associated with a higher incidence of
maternal vascular malperfusion (MVM) and chorioamnionitis
(CA), whilst fetal vascular malperfusion, severe acute fetal
hypoxia and villitis of unknown etiology are similar in both
groups. This study further strengthens the results from a
previous sub-analysis that prolongation of gestation has no
additional benefits and even increases the prevalence of MVM
and CA in FGR; both placental findings are associated with
an increase in children born with severe growth restriction
and are possibly associated with unfavorable outcome at
later ages.
Strengths and Limitations of the Study
The strengths of this study are a dedicated, uniform examination
of the placentas, done by one perinatal pathologist unaware
of clinical details, by the latest criteria, in a large number
of placentas from pregnancies complicated with FGR. In this
sub-study prolongation of pregnancy is 2 days less than the
original DIGITAT study and the weight gain in that period
is on average less per day (13 grams per day in the original
study vs. 7.5 grams in this study). This combined with the
fact that more inclusions showed a decline in AC growth than
the original study and finally that more inductions in the
expectant management group of this analysis (66%) occurred
than in the original study (25.5%) indicates that there is probably
an inclusion bias with the more severe cases included in
the study. We however believe that this inclusion bias does
not undermine the results of this study. In the induction
group there may also be a similar trend in sending more
placenta’s of clinically severe cases to the pathologist than
the clinically less severe cases. A limitation of this study
is that only 29% cases of the original DIGITAT trial were
included, due to the availability of placental histological samples,
which were collected from all participating hospitals in the
Netherlands. We believe it is of great importance to analyze
the placenta histopathology for understanding the underlying
pathophysiology, especially in cases of FGR in which a common
mechanism is placental insufficiency. All in all, we found
that expectant management of late FGR is associated with
increased maternal vascular malperfusion and chorioamnionitis.
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Further studies on the clinical implications of these findings
are warranted.
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